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Abstract 
Spinal cord tumors in pediatric patients are
rare, representing less than 1% of all central
nervous system tumors. Two cases of pediatric
primary intramedullary spinal cord glioblastoma
at  ages  14  and  8  years  are  reported.  Both
patients presented with rapid onset paraparesis
and quadraparesis. Magnetic resonance imag-
ing in both showed heterogeneously enhancing
solitary mass lesions localized to lower cervical
and  upper  thoracic  spinal  cord  parenchyma.
Histopathologic  diagnosis  was  glioblastoma.
Case #1 had a small cell component (primitive
neuroectodermal  tumor-like  areas),  higher
Ki67, and p53 labeling indices, and a relatively
stable karyotype with only minimal single copy
losses  involving  regions:  Chr8;pter-30480019,
Chr16;pter-29754532,  Chr16;56160245-
88668979,  and  Chr19;32848902-qter  on  retro-
spective  comparative  genomic  hybridization
using formalin-fixed, paraffin-embedded sam-
ples. Case #2 had relatively bland histomorph -
ology and negligible p53 immunoreactivity. Both
underwent multimodal therapy including gross
total  resection,  postoperative  radiation  and
chemotherapy. However, there was no signifi-
cant improvement in neurological deficits, and
overall survival in both cases was 14 months.
This  report  highlights  the  broad  histological
spectrum  and  poor  overall  survival  despite
multi  modality therapy. The finding of relatively
unique  genotypic  abnormalities  resembling
pediatric embryonal tumors in one case may
highlight the value of genome-wide profiling in
development  of  effective  therapy.  The  differ-
ences  in  management  with  intracranial  and
low-grade spinal cord gliomas and current man-
agement issues are discussed.
Introduction
Spinal cord tumors are rare in children, rep-
resenting less than 1% of all central nervous
system (CNS) tumors.
1-5 Within this small frac-
tion, intramedullary spinal cord (ISC) tumors
constitute  about  35%  of  the  spinal  tumors
found in children
6,7 compared to 5% in adults.
8
Low-grade gliomas such as ependymomas and
astrocytomas  account  for  the  majority,  with
only about 1-3% being high-grade gliomas.
6 A
recent  review  of  the  cases  of  pediatric  ISC-
glioblastoma (GBM) reported in the last two
decades  is  summarized  in  Table  1.  Patients
were  treated  with  multimodality  therapeutic
regimens similar to their adult counterparts.
The roles of maximum safe surgical resection
and radiotherapy are well established in the
treatment  of  pediatric  high-grade  glioma  in
the intracranial location, and in non-infiltra-
tive spinal cord tumors, but not in high-grade
spinal cord gliomas where recent studies dis-
courage the use of radical surgery.
4 The role of
chemotherapy remains undefined.
9 Based on
this limited dataset, critical underlying genom-
ic events and the determination of the optimal
therapeutic approach in this rare disease are
unknown.
3 This report describes two cases of
pediatric  primary  ISC-GBM.  Both  had  gross
total resection, and were treated with adjunct  -
ive chemotherapy and radiation therapy as per
the  Children’s  Oncology  Group  protocol
ACNS0126 for intracranial gliomas extrapolat-
ed to high-grade spinal cord gliomas.
10 Results
of comparative genomic hybridization in one
case in whom adequate tissue and call rate
was available is also provided. A review of per-
tinent literature aims to provide a comparative
and balanced perspective.
Case #1
A  14-year-old  Asian–American  female  pre-
sented  with  a  six-month  history  of  lower
extremity  dysesthesias,  which  progressed  to
lower extremity weakness and gait difficulties
several  days  before  presentation.  Magnetic
resonance  imaging  (MRI)  of  the  brain  and
spine  performed  at  an  outside  hospital
(images  currently  unavailable)  revealed  an
intramedullary  enhancing  mass  extending
from the level of the sixth cervical (C6) to fifth
thoracic (T5) vertebra. She underwent cervical
and  thoracic  laminectomies  with  gross  total
resection  of  the  tumor.  The  histopathologic
diagnosis  was  GBM  (Figure  1A-E).  Post  -
operatively, the patient had paraplegia and an
upper  extremity  strength  of  1/5,  which
improved to 4/5 within two weeks with steroids
and  physical  therapy.  During  rehabilitation,
she  required  treatment  for  wound  infection
and  dehiscence.  She  began  the  Children’s
Oncology Group protocol ACNS0126 with radi-
ation therapy and chemotherapy in the treat-
ment of high-grade glioma.
10She received 5040
cGy to her cervical and thoracic spine in 28
evenly divided fractions. On the fifth day of
radiation  therapy,  she  began  oral  temozolo-
mide at 90 mg/m
2/day for six weeks, followed by
a four-week rest. Maintenance therapy consist-
ed of 10 courses of 28-day cycles of oral temo-
zolomide 200 mg/m
2/day for five days, followed
by 23 days of rest. During this therapy, she
reported  subjective  improvement  in  leg
strength, but remained wheelchair-bound.
MRI of the spine six months after resection
showed progression of the tumor, extending
from the level of C5 to T3. Post-radiotherapy
changes were seen throughout the spinal axis.
Nine months after resection, MRI of the spine
showed a stable lesion, with cord expansion
and  myelomalacia  in  a  similar  distribution.
Whole-body PET imaging from the skull to the
thigh was negative for metastasis or lymph -
adenopathy. Fourteen months after resection,
the patient died while in hospice care.
Case #2
An eight-year-old African–American female
presented with a three-week history of neck
pain and weakness, which progressed to sig-
nificant weakness in all extremities. MRI of
the brain and spine revealed an intramedullary
enhancing mass originating from the central
portion of the spinal cord, extending from the
level of C3 to T4 with significant cord expan-
sion from C3 to T3 (Figure 2A-E). Of note, pre-
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operative cerebrospinal fluid cytology was neg-
ative for malignancy. She underwent C1 to T2
laminectomies with gross total resection of the
tumor and posterior osteoplastic arthrodesis. A
histopathologic diagnosis of GBM was made
(see  Pathology  section  for  details).  Post  -
operatively, she was found to have sensations
bilaterally,  movement  in  both  upper  extrem  -
ities, and some movement in the right foot.
She was referred to the Rehabilitation Center,
where she began treatment according to the
Children’s  Oncology  Group  protocol
ACNS0126.
10 She received fractionated radia-
tion therapy to her cervical and thoracic spine,
and  oral  temozolomide  therapy  as  described
for case #1. One year after resection, MRI of
the spine demonstrated that her tumor had not
progressed. She had developed an acute angle
kyphotic deformity, most pronounced at C4 to
C5, with spinal cord compression. There was
no subsequent improvement in her neurological
deficits.
Fourteen months after resection, she present-
ed to the Emergency Department and required
intubation for respiratory failure and treatment
for severe bronchopneumonia. MRI of the brain
and spinal cord showed interval development of
edema  and  contrast  enhancement  from  the
lower medulla to the level of T2, consistent with
recurrence.  On  her  fifth  hos  pital  day,  she
became unresponsive to stimuli and had absent
corneal reflexes. The patient died the next day,
14 months after tumor resection.
Pathology 
Histological  examination  of  the  resected
masses in both cases revealed high-grade infil-
trating astrocytic neoplasms with necrosis and
microvascular  proliferation.  No  obvious
pseudopalisading around the areas of necrosis
were seen in either case. Individual neoplastic
cells  demonstrated  significant  nuclear  pleo-
morphism, anaplasia and high mitotic activity
with  scattered  apoptotic  bodies  (Figures  1A
and B; 2F-J, respectively), including small cells
focally  resembling  a  primitive  neuroectoder-
mal tumor (PNET) but with microvascular pro-
liferation  (Figure  1B).  A  diagnosis  of  GBM,
WHO  grade  IV,  was  rendered.  Diffuse
immunopositivity for glial fibrillary acidic pro-
tein (GFAP) supported the diagnoses in both
cases (Figures 1C and 2K).
In case #1, there was a small cell component
and more conspicuous anaplasia as compared
to  case  #2.  The  neoplastic  cells  in  case  #1
showed  a  high  Ki67  (MIB1)  immunohisto-
chemical nuclear labeling index of up to about
30%, and a high p53 labeling index of up to
about  70%  (Figure  1D  and  E  respectively).
Immunostain  for  epidermal  growth  factor
receptor (EGFR) was negative. The ultrastruc-
tural evaluation in case #1 revealed pleomor-
phic cells with short bulbous projections and a
paucity of organelles except for mitochondria.
The nuclei were pleomorphic with conspicu-
ous heterochromatin. Glial filaments in every
cell were scattered throughout the cytosol in
discreet  bundles,  often  associated  with
Rosenthal bodies. Microtubules were found in
close-packed  bundles  or  loose  arrays  in  the
cytosol  and  cellular  projections.  Tumor  sam-
ples  from  case  #1,  were  previously  analyzed
using  array  comparative  genomic  hybridiza-
tion (aCGH). These analyses revealed a rela-
tively stable karyotype with only minimal sin-
gle  copy  losses  involving  regions:  Chr8;pter-
30480019,  Chr16;pter-29754532,  Chr16;
56160245-88668979,  and  Chr19;32848902-
qter.
11 None of the frequent losses, gains, and
amplifications seen in adult GBM
12 were iden-
tified in this sample (see Discussion).  
In case #2, the neoplastic cells were relative-
ly bland as compared to case #1. High-grade
cytological  features  were  not  apparent  on
frozen sections, but diagnostic features were
seen  on  FFPE  sections.  The  neoplastic  cells
showed  a  high  Ki67  (MIB1)  immunohisto-
chemical nuclear labeling index of up to about
20%, but a rather low p53 labeling index of less
than  5%  (Figure  2L  and  M,  respectively).
Immunostain  for  synaptophysin  localized  to
the background neuropil, but did not stain the
tumor cells. The FFPE tissue from this case
was not found to be optimal for aCGH.
Case Report
Figure 1. Case #1. (A) Densely cellular neoplasm, with hyperchromatic and pleomorphic
astrocytic cells in a well-formed fibrillary background meshwork, with focal necrosis
(H&E stain; 100X magnification). (B) Densely cellular infiltrating portion of the neo-
plasm, with markedly hyperchromatic and pleomorphic overlapping astrocytic cells in a
rather  sparse  fibrillary  background  with  focal  necrosis,  including  small  cells  focally
resembling  a  primitive  neuroectodermal  tumor  but  with  microvascular  proliferation
(H&E stain; 200X). (C) The tumor shows diffuse glial fibrillary acidic protein (GFAP)
positivity with dense fibrillary network in portions (GFAP stain; 400X). (D) The tumor
shows a high Ki67 (MIB1) immunohistochemical nuclear labeling index of up to about
30% (Ki67 stain; 200X). (E) The tumor shows a high p53 immunohistochemical nuclear
labeling index of up to about 70% (p53 stain; 200X).[Rare Tumors 2010; 2:e48] [page 137]
Discussion
The ISC is the location of only one third of
1% of pediatric CNS tumors.
1,3 Of these, high-
grade gliomas such as the two ISC-GBM cases
reported here constitute only about 1-3%, far
outnumbered  by  the  low-grade  gliomas  and
ependymomas.
6 These  are  rare  tumors,  and
even with many recent advances in preopera-
tive  imaging,  micro-neurosurgery  and  radia-
tion/chemotherapy protocols,
13 the overall sur-
vival  after  multimodality  therapy  has  been
comparable  to  that  in  adults.
14,15 A  review  of
cases of pediatric ISC-GBM reported in the last
two decades is summarized in Table 1.
Clinical features
The clinical presentation of any ISC tumor
relates  to  the  region  of  the  spinal  cord
involved.
3,16 Up to 60% of pediatric ISC astrocyt  -
omas can show holocord presentation,
17 which
is unusual in adults. The most common symp-
toms in pediatric ISC tumors are pain (42%),
motor  regression  (36%),  gait  abnormalities
(27%),  torticollis  (27%),  and  progressive
kyphoscoliosis  (24%).
6 The  cases  reported
here presented with non-specific neck pain or
lower  extremity  dysesthesias,  which  soon
worsened  to  progressive  weakness  and  gait
difficulties.  In  a  recent  study,  preoperative
symptom duration of more than 180 days was
associated with improved survival in infiltra-
tive spinal cord astrocytomas.
4
Radiological features
Most cases of ISC-GBM showed MRI imag-
ing  characteristics  similar  to  intracranial
GBM. Occasional atypical features included an
Case Report
Table 1. Main clinicopathologic data in the reported pediatric cases of histopathologically confirmed intramedullary glioblastomas of
the spinal cord.
Case Ref. Age/sex Site Surgery RT CTX Rec F/U (months) Outcome
1 31 4 M Holocord Partial None + +  37 DOT
2 31 13 F Cervical Total ++ + (CSF) 15 DOD
3 31 15 M Cervical Partial -+ + (CSF) 8 DOT
4 20 16 F T12-L1 Subtotal + NA + (CSF) 6 DOD
5 20 14 M T12-L1 Subtotal +? + (CSF) 4 DOD
67 <3 NA Subtotal ++ + 23 Alive
7 38 12 C1-C7 Partial NA NA NA NA Alive
8 39 20 M T12-L1 Subtotal +- + (CSF) 11 DOD
93 1.8 F C7-T7 Total 55 Gy -+ 14 DOD
10 3 1.4 M C7-T2 Subtotal 38 Gy ++ 13 DOD
11 3 1.0 M C3-T7 Biopsy 48 Gy ++ 24 DOD
12 13 0.7 M C5-L1 Total 40 Gy NA - 144 Alive
13 13 17.9 M T9-L1 Subtotal None NA -3 DOD
14 16 19 F NA NA NA NA NA 9 DOD
15 16 18 F C7-T7 Total + NA NA 21 DOD
16 16 3 M T7 Biopsy ++ + (CSF) 13 DOD
17 16 14 M C2-C7 Subtotal ++ NA 9 DOD
18 16 19 M C4-C6 Subtotal + NA NA 12 DOD
19 17 14 M T12-L1 Total NA NA + (CSF) 9 NA
20 5 12 M T11-L1 Subtotal CSI 48.6 NA + (CSF) 7 NA
21 5 9 F T11-L2 Subtotal Focal 38 NA + (CSF) 1 NA
22 5 23 F C3-5 Total Focal 50.4 NA Local 24 NA
23 5 11 F C1-T1 Total Focal 50 NA - 150 Stable
24 5 5 F C3-T2 Biopsy CSI 38, Focal 48 NA - 239 Stable
25 5 10 M C1-2,T6-8 Subtotal CSI 48.4, focal 66 NA + (CSF) 2 NA
26 5 10 M C2-T6 Subtotal Focal 54 NA Local 72 NA
27 5 11 F C2-C7 Subtotal Focal 54 NA + (CSF) 1 NA
28 5 18 F C7-T7 Total Focal 55 NA Local 10 NA
29 5 14 M C7-T2 Subtotal CSI 38.5 NA Local 4 NA
30 5 10 F C3-T7 Biopsy Focal 48 NA + (CSF) 14 NA
31 5 17 M C1-5 Subtotal Focal 54 NA Local 4 NA
32 5 13 F C1-T1 Biopsy Focal 54 NA + (CSF) 1 NA
33 5 3 M C3-T8 Subtotal CSI 34.2, focal 55.2 NA - 88 stable
34 5 15 F T10-11 Subtotal CSI 39.6, focal 51.3 NA + (CSF) 1 NA
35 5 12 M T12 Subtotal Focal 54 NA + (CSF) 4 NA
37 5 9 F T2-7 Subtotal CSI 36, focal 54 NA - 10 Stable
38 Current 14 F C6-T5 Total ++ + 14 DOD
39 Current 8 F C3-T4 Subtotal ++ + 14 DOD
RT, radiation therapy; CTX, chemotherapy; Rec, recurrence; M, male; F, female; NA, not available; CSI, craniospinal irradiation; CSF, cerebrospinal fluid; DOT, died of toxicity; DOD, died of disease.[page 138] [Rare Tumors 2010; 2:e48]
Case Report
Figure 2. Case #2. (A) T1 weighted sagittal mag-
netic resonance images without contrast show an
intramedullary hypointense mass lesion present
within the central portion of the cervical spinal
cord from C3 to T3 levels, producing expansion.
(B) T1 weighted sagittal MR images with con-
trast  show  an  intramedullary  enhancing  mass
lesion present within the central portion of the
cervical spinal cord, originating from the region
of the central canal, producing expansion. The
spinal cord measures 13 mm at the greatest AP
diameter. The mass shows rim enhancement with
central cystic changes and is surrounded by nor-
mal-appearing  spinal  cord.  This  mass  extends
from the level of the obex inferiorly to the T4 ver-
tebral body. The maximum bulk of the mass is
present from C3 to T3 levels. This mass produces
remodeling of the posterior vertebral bodies most
notably at C4 to C7. (C) T2 weighted sagittal
MRI showing an expansile intramedullary mass
lesion present within the cervical spinal cord. (D)
Post-contrast T1 weighted axial MRI showing an
enhancing expansile intramedullary mass lesion
present within the central portion of the spinal
cord. (E) Post-contrast T1 weighted axial MRI
showing  a  ring-enhancing  expansile  intrame  -
dullary  mass  lesion  present  within  the  central
portion of the spinal cord. (F) Moderate to focal
densely  cellular  neoplasm  with  moderately
hyperchromatic  and  pleomorphic  loosely
arranged  astrocytic  cells,  with  focal  marked
microvascular proliferation (H&E stain; 200X).
(G) Areas of necrosis within the astrocytic neo-
plasm.  No  pseudopalisading  is  appreciated
(H&E stain; 100X). (H) Moderate to focal dense-
ly cellular neoplasm with moderately hyperchro-
matic  and  pleomorphic  astrocytic  cells,  with
more than one mitosis in one high-power field,
and with focal moderate microvascular prolifera-
tion (H&E stain; 400X). (J) Moderately hyper-
chromatic and pleomorphic astrocytic cells, with
more than one mitosis in one high-power field
(H&E stain; 400X). (K) Irregular infiltration of
diffusely  immunopositive  neoplastic  astrocytic
cells, with negative images of hyperplastic vessels
(GFAP stain; 100X). (L) The tumor shows a high
Ki67  (MIB1)  immunohistochemical  nuclear
labeling index of up to about 20% (Ki67 stain;
200X). (M) The tumor shows a negligible p53
immunohistochemical nuclear labeling index of
less than 5% (p53 stain; 200X).[Rare Tumors 2010; 2:e48] [page 139]
expansive ISC mass, with signal intensity com-
patible with either low-grade astrocytoma or
ependymoma on T1 weighted images.
17 Others
were  exophytic  with  features  suggesting
meningioma.
16 Both  current  cases  showed
enhancing ISC masses on MRI that were wor-
risome for high-grade glioma.
Surgical resection
In low-grade non-infiltrative tumors such as
ependymomas or pilocytic astrocytomas, radi-
cal  excision  using  recent  microsurgical
advances
1 before the onset of significant dis-
ability is the standard of care and often results
in improved risk-benefit ratio, and a good long-
term  prognosis.
18 However,  in  high-grade
tumors, the value of surgery is less clear. In
pediatric intracranial malignant astrocytomas,
significant  improvement  in  progression-free
survival  (PFS)  has  been  reported  following
radical tumor resection.
19 The data in pediatric
ISC  tumors  are  debatable.  In  some  studies,
gross  total  or  subtotal  resection  could  be
achieved in a majority of patients with mini-
mal short-term morbidity.
3,5,7 Radio-cordectomy
and  cordotomy  was  also  associated  with
improved  survival.
8 However,  radical  tumor
resection  of  high-grade  spinal  cord  gliomas
has not been shown to alter the relentless clin-
ical deterioration and short overall survival of
this devastating tumor, and instead carries the
risk of permanent neurological sequelae and
impairment of the quality of the patients’ brief
remaining lives.
4,20 The current recommenda-
tion  in  high-grade  ISC  tumors  is  diagnostic
biopsy  followed  by  postoperative  radiation
therapy,
3,4 and to reserve extensive surgery for
anaplastic  astrocytomas
5 and  palliation  in
patients in whom RT is not well-tolerated or
contraindicated.
3,4 The rationale behind radical
surgery  in  select  cases  of  high-grade  spinal
cord gliomas includes obtaining adequate tis-
sue for diagnosis, cytoreductive tumor debulk-
ing, and helping relieve pain.
20 In our study,
although both patients had a similar poor out-
come, the histological diversity, with a small
cell component resembling PNET in case #1,
lack of overt high-grade cytology on frozen sec-
tions  in  case  #2,  and  the  resulting  need  to
establish correct diagnosis along with debulk-
ing justify maximal safe resection.
Pathological features
Histological  type  and  grade  are  the  most
important prognostic factors in ISC glioma.
4,5,16
The histopathological features of ISC-GBM are
identical  to  intracranial  tumors  in  adults,
15
except for possibly increased leptomeningeal
involvement  owing  to  proximity  to  the  sub-
arachnoid space.
5,6 The current cases showed a
wide  histological  spectrum  ranging  from
PNET-like areas in case #1 to relatively bland
areas in case #2. The predictive value of MIB-1
labeling index is unclear,
14,16 with no statistical-
ly significant difference in outcome between
cases  with  MIB-1  labeling  index  above  and
below 5%.
16In our report, both cases were asso-
ciated  with  high  Ki67  labeling  indices.
Pediatric high-grade gliomas in children over
three years of age have been found to have a
higher frequency of TP53 mutations and over-
expression (40%),
21 indicating potential exist  -
ence of two different molecular pathways of
tumorigenesis.
21,22 The  relationship  of  p53
overexpression  to  progression  to  GBM,
14,23
worse  progression-free  survival,
24 and  brain
metastases  in  spinal  GBM
15 found  in  some
studies, were not reproduced in other studies.
16
In our two cases, p53 immunohistochemical
labeling indices were different (70% in case #1
vs. 5% in case #2), yet they had similar overall
survival of 14 months.
Adult GBM shows a characteristic range of
cytogenetic abnormalities that occur at high
frequency  in  subsets  of  tumors.  Loss  of
chromo  some 10, deletion of the p16 gene in
9p21 (often homozygous) amplification of the
EGFR  locus,  and  gain  of  chromosome  7  are
among  the  most  common  events
25 seen  in
these  tumors.  None  of  these  cytogenetic
abnormalities, or any others less frequent but
typical  of  adult  GBM,  were  seen  in  case  #1
described in this report. Our findings correlate
with pediatric glioblastomas in general
11 and
are similar to other recent reports on pediatric
GBM.
26 Although losses involving 8p, 16p, and
16q  are  reported  occasionally  in  adult  GBM,
they are not frequent in pediatric GBM. Losses
involving the long arm of chromosome 19 are
also  infrequent  and  more  typically  found  in
anaplastic oligodendroglioma.
27 In fact, losses
involving 8p and 16q are far more typical of
medulloblastomas.
28 From  a  genetic  stand-
point, therefore, the pediatric GBM described
here is more typical of pediatric brain tumors
than adult GBM.
Radiation therapy
Radiation therapy (RT) provides temporary
clinical  and  radiographic  improvement,  and
prolongs  survival  in  high-grade  gliomas  for
some pediatric patients, yet it is rarely cura-
tive.
29 An  exception  is  infants  and  children
under  three  years  of  age  in  whom  adjuvant
treatments  are  reserved  for  tumor  recur-
rence.
7,29 The risk of post-radiation growth sup-
pression or second malignancy following treat-
ment  of  non-infiltrative  spinal  cord  tumors
such  as  ependymomas  or  pilocytic  astro  -
cytomas is not an issue in high-grade gliomas
owing to their short life span. In current treat-
ment protocols, adult patients with high-grade
gliomas receive 5,400-6,000 cGy local radiation
to the brain tumor bed, with a peri-tumoral
margin  to  account  for  tumor  infiltration,  in
daily fractions of 180-200 cGy.
8 The spinal cord
is less tolerant of radiation, so the radiation
dose was restricted to 5040 cGy in both our
patients,  to  avoid  the  risk  of  transverse
myelitis. As RT is now considered to be the
standard  management  in  infiltrative  high-
grade  ISC  astrocytomas,
4 and  many  such
patients present with near paraplegia, higher
doses up to 5940 cGy have been reported in the
literature. However, when used in conjunction
with chemotherapy or potential radiosensitizer
(TMZ), a lower dose of radiotherapy is reason-
able. In a recent study, patients with infiltra-
tive  spinal  cord  astrocytomas  who  received
postoperative RT to a dose of >3500 cGy had a
significantly better survival than those with a
lesser dose or no RT.
4 Considering the wide
range of radiation dose reported (Table 1), the
dose is best individualized. 
Chemotherapy
There is no proven effective chemotherapy
for high-grade gliomas in children. Yet, most
children  with  high-grade  gliomas  receive
chemotherapy in addition to surgery and radi-
ation therapy.
29,30 There are reports of improved
survival in pediatric high-grade ISC tumors by
addition of chemotherapy.
31,32 The optimal tim-
ing of chemotherapy and radiation (preopera-
tive vs. postoperative) is debated. While preop-
erative chemotherapy is considered to provide
optimum  treatment  to  undisturbed  tumor
microvasculature,
3,33 postoperative chemother-
apy may be more efficacious owing to disrup-
tion  in  the  blood-brain  barrier.
30 Drugs  that
have  been  used  in  clinical  trials  in  the
Children’s  Oncology  Group  studies  include
temozolamide,  anti-angiogenesis  agents,
immunotoxins,  and  other  maturational  and
differentiating  agents.  In  this  report,  both
patients  presented  with  a  rapid  decline  in
function, necessitating urgent surgical inter-
vention prior to other modalities.
Outcomes 
Patients with infiltrative astrocytoma of the
spinal  cord  had  uniformly  poor  survival
4,19
regardless of age.
4 Cases with ISC-GBM invari-
ably progress despite aggressive chemotherapy
and radiation therapy,
4,5,8,20 and long-term func-
tional outcomes have been poor.
1,4,5,34,35 For pedi-
atric intracranial malignant gliomas, the me  -
dian  survival  with  conventional-dose
chemotherapy and radiation therapy is 11-24
months, with an overall survival of 5-20% at
five years,
15,32 with a worse outcome for GBM
than grade III gliomas.
30,36 Yet, most publica-
tions have not shown a survival advantage in
pediatric  intramedullary  high-grade  gliomas
with multimodality therapy,
16,37 owing to high
histological grade, lack of adequate cleavage
plane between tumor and spinal tissue, and
easy access to CSF.
7,20
Median overall survival has been reported to
be shorter with neuraxis dissemination than
local  failure  alone.
5 The  reportedly  higher
lepto  meningeal  involvement  in  spinal  GBM
Case Report[page 140] [Rare Tumors 2010; 2:e48]
(39%) compared to cerebral GBM (27%) indi-
cates CSF spread as a more important cause of
death  than  direct  brainstem  involvement,
thereby  necessitating  regular  MRI  and  CSF
cytology.
6,15 In  our  cases,  preoperative  CSF
cytology  did  not  show  neoplastic  cells.  The
patients died from complications of respiratory
failure,  likely  a  result  of  MRI-detected  local
tumor recurrence and brainstem involvement.
Conclusions
The spinal cord is a rare site of pediatric
GBM, which has a poor overall survival despite
multimodality therapy. The novel aspects of the
study  include  diverse  histological  spectrum,
treatment with Children’s Oncology Group pro-
tocol  ACNS0126,  and  relatively  unique  CGH
findings, which correlate with pediatric GBM
in  general.
11 Diagnostic  biopsy  followed  by
radiation  with/without  chemotherapy  is  the
standard of care, with the option of radical sur-
gery  considered  based  on  judicious  assess-
ment of risk-benefit ratio. The finding of rela-
tively unique genotypic abnormalities resem-
bling pediatric embryonal tumors in one of the
cases presented here highlights the potential
value of genome-wide profiling in the develop-
ment of effective treatment strategies.
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